Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Public ClinicalTrials.gov record NCT05153330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Study identification
- NCT ID
- NCT05153330
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
- Acute Lymphoblastic Leukemia
- Acute Mixed-Phenotype Leukemia
- Acute Myeloid Leukemia
- Cancer
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myeloma, Plasma-Cell
- Myelomatosis
- Plasma Cell Myeloma
- Progression
- Refractory
- Small Lymphocytic Lymphoma
Interventions
- BMF-219 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2022
- Primary completion
- Feb 12, 2025
- Completion
- May 1, 2025
- Last update posted
- Jul 2, 2025
2022 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Irvine | Irvine | California | 92697 | — |
| University of Southern California Norris Cancer Center | Los Angeles | California | 90033 | — |
| UCLA Department of Medicine | Los Angeles | California | 90095 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Blood & Marrow Transplant Group of GA (Northside Hospital) | Atlanta | Georgia | 30342 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Gainesville | Virginia | 20155 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05153330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05153330 live on ClinicalTrials.gov.